A BILL 
To require the Government Accountability Office to study 
the role pharmaceutical benefit managers play in the 
pharmaceutical supply chain and provide Congress with 
appropriate policy recommendations, and for other pur-
poses. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pharmacy Benefit 
4
Manager Accountability Study Act of 2021’’. 
5
20:28 May 03, 2021
H1829
2 
•HR 1829 IH
SEC. 2. GAO STUDY. 
1
Not later than 1 year after the date of enactment 
2
of this Act, the Comptroller General of the United States 
3
shall submit to the Committee on Ways and Means, the 
4
Committee on Energy and Commerce, and the Committee 
5
on Education and Labor of the House of Representatives 
6
and to the Committee on Finance and the Committee on 
7
Health, Education, Labor, and Pensions of the Senate a 
8
report that— 
9
(1) addresses, at minimum— 
10
(A) the role that pharmacy benefit man-
11
agers play in the pharmaceutical supply chain; 
12
(B) the state of competition among phar-
13
macy benefit managers, including the market 
14
share for the Nation’s 10 largest pharmacy 
15
benefit managers; 
16
(C) the use of rebates and fees by phar-
17
macy benefit managers, including data for each 
18
of the 10 largest pharmacy benefit managers 
19
that reflects, for each drug in the formulary of 
20
each such pharmacy benefit manager— 
21
(i) the amount of the rebate passed on 
22
to patients; 
23
(ii) the amount of the rebate passed 
24
on to payors; 
25
20:28 May 03, 2021
H1829
3 
•HR 1829 IH
(iii) the amount of the rebate kept by 
1
the pharmacy benefit manager; and 
2
(iv) the role of fees charged by the 
3
pharmacy benefit manager; 
4
(D) whether pharmacy benefit managers 
5
structure their formularies in favor of high-re-
6
bate prescription drugs over lower-cost, lower- 
7
rebate alternatives; 
8
(E) the average prior authorization ap-
9
proval time for each of the 10 largest pharmacy 
10
benefit managers; 
11
(F) factors affecting the use of step ther-
12
apy in each of the 10 largest pharmacy benefit 
13
managers; and 
14
(G) the extent to which the price that 
15
pharmacy benefit managers charge payors, such 
16
as the Medicare program under title XXVIII of 
17
the Social Security Act (42 U.S.C. 1395 et 
18
seq.), State Medicaid programs under title XIX 
19
of the Social Security Act (42 U.S.C. 1396 et 
20
seq.), the Federal Employees Health Benefits 
21
Program under chapter 89 of title 5, United 
22
States Code, or private payors, for a drug is 
23
more than such pharmacy benefit managers pay 
24
the pharmacy for the drug; and 
25
20:28 May 03, 2021
H1829
4 
•HR 1829 IH
(2) provides recommendations for legislative ac-
1
tion to lower the cost of prescription drugs for con-
2
sumers and payors, improve the efficiency of the 
3
pharmaceutical supply chain by lowering inter-
4
mediary costs, improve competition in pharmacy 
5
benefit management, and provide transparency in 
6
pharmacy benefit management. 
7
Æ 
20:28 May 03, 2021
H1829
